News|Articles|November 28, 2013

Baxter Recalls One Lot of Nitroglycerin in 5% Dextrose Injection

Baxter has issued a voluntary recall of one lot of nitroglycerin in 5% dextrose injection after particulate matter was found in one vial.

Baxter has issued a voluntary recall of one lot of nitroglycerin in 5% dextrose injection after particulate matter was found in one vial. This recall is being conducted with the knowledge of the US FDA.

Injection of particulate matter can lead to blockage of blood vessels. It can also cause inflammation, particularly in the lungs, and local irritation of blood vessels due to the presence of foreign material. No adverse events associated with this issue have been reported to date.

Baxter's nitroglycerin in 5% dextrose injection is packaged in 250 mL glass containers, with 12 glass containers per carton. The affected product code is 1A0694, and the affected lot number is G105197. Products affected by this recall were distributed in Colombia, Saudi Arabia and the United States between January 17, 2013, and October 10, 2013. Baxter has notified its customers not to use product from the recalled lot and to return all affected product.

Source: Baxter


Related to this article

Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma Logistician Using IoT Based On Blockchain | Image Credit: ©leowolfert -stock.adobe.com
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.